Best Cell Therapy CDMOs in Germany
· updated as new inspection, certificate, and trial data enters the platform
7
CDMOs tracked
6
Fully scored
3
With FDA records
8
FDA inspections
10
EMA/MHRA GMP certs
Cell therapy CDMOs manufacture living products — CAR-T, TCR, NK, and stem-cell therapies — where the process is the product. Autologous programs add patient-scheduling and chain-of-identity demands that allogeneic, batch-based programs avoid.
The right cell therapy CDMO depends on autologous vs allogeneic experience, vector sourcing, closed-system processing, and cold-chain logistics. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
FDA inspection outcomes across these CDMOs: 4 NAI (no action), 4 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: United States (7), Germany (6), UNITED STATES (4), China (1).
Last updated 2026-08-18. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
MK
Merck KGaA / MilliporeSigma (CDMO)
Darmstadt, DE · St. Louis, MO
|
81.8 | 98.6 | 2 insp · 2 GMP | — | 22 programs |
| 2 |
MB
Miltenyi Biotec
Bergisch Gladbach, Germany
|
74.6 | 100.0 | 0 insp · 2 GMP | — | 8 programs |
| 3 |
MN
Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
|
83.5 | 100.0 | 1 insp · 6 GMP | Limited | 0 programs |
| 4 |
EF
Eurofins CDMO
Planegg, DE · San Diego, CA
|
81.6 | 100.0 | 5 insp · 0 GMP | — | 0 programs |
| 5 |
CZ
Cellex Cell Professionals
Cologne, Germany
|
59.0 | — | — | — | 0 programs |
| 6 |
CX
CellGenix
Freiburg, DE
|
56.5 | — | — | — | 0 programs |
| — |
Fresenius Kabi
Bad Homburg, Germany
|
Profiled | — | — | — | 0 programs |
What to evaluate in a Cell Therapy CDMO
Autologous vs allogeneic
Autologous needs per-patient scheduling, chain-of-identity, and short turnaround; allogeneic needs scalable batch processing and a master cell bank strategy. Pick a CDMO proven in your model.
Vector & raw materials
Most cell therapies need a viral vector. Confirm whether the CDMO makes vector in-house or coordinates an external supplier, and how that affects timelines.
Closed-system & cleanrooms
Closed, automated processing reduces contamination risk and labor. Ask about cleanroom grade, automation platforms, and parallel-suite capacity.
Cold chain & logistics
Cryopreservation and chain-of-custody are critical for living cells. Evaluate the CDMO's cold-chain and apheresis-to-infusion logistics.
What makes the German CDMO cluster distinctive within Europe?
Germany's CDMO base combines three attributes that shape sponsor decisions: (1) strong biologics + advanced-therapy depth — BioNTech's Marburg site is one of the largest single-facility mRNA operations globally, Boehringer Ingelheim BioXcellence operates commercial-scale biologics at Biberach, and Rentschler carries deep mAb + biosimilar experience; (2) engineering discipline — German pharmaceutical manufacturing has a reputation for process rigor that translates into strong FDA and EMA inspection outcomes; (3) proximity to European pharmaceutical R&D centers, which reduces tech-transfer coordination cost. German CDMOs generally hold BfArM + EMA + MHRA + FDA certifications concurrently for global-market-supplying facilities.
Which German CDMOs specialize in advanced-therapy modalities (viral vector, cell therapy, mRNA)?
Germany hosts substantial advanced-therapy CDMO capacity. Cross-reference with modality pages to filter: mRNA CDMOs (BioNTech Manufacturing Services is Germany's largest), AAV CDMOs, lentiviral CDMOs, cell therapy CDMOs, or the viral vector umbrella. The individual CDMO profile pages surface facility-level modality coverage — critical for advanced-therapy programs where the specific German site's containment class and analytics platform matter more than country-level aggregates.
German CDMOs supplying US and Asian markets
German CDMOs with FDA and Asian regulator inspection history qualify to supply global markets; those without cross-jurisdictional inspection posture are typically limited to EU and MHRA scope. Cross-check with the US region ranking and Asia region ranking to identify German-headquartered CDMOs with global footprint. The Signal Score's Quality Compliance pillar captures FDA + EMA + MHRA data directly, so cross-jurisdictional German CDMOs typically rank higher on this pillar than EU-only competitors.
Cell Therapy CDMOs — Frequently Asked Questions
Who are the top Cell Therapy CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Cell Therapy CDMOs include Merck KGaA / MilliporeSigma (CDMO), Miltenyi Biotec, Minaris Advanced Therapies. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Cell Therapy CDMOs have FDA inspection records?
CDMO Signal tracks 3 Cell Therapy CDMOs with FDA inspection records and 10 EMA/MHRA GMP certificates across the group.
What should I look for in a cell therapy CDMO?
Match the CDMO to your model: autologous needs chain-of-identity and fast turnaround; allogeneic needs scalable batch processing. Confirm vector sourcing, closed-system processing, cold-chain logistics, and a clean FDA and EMA/MHRA record.
Do cell therapy CDMOs make their own viral vectors?
Some do in-house; others coordinate an external vector supplier. In-house vector can shorten timelines and simplify supply, but a strong external partner is common. Check each profile's modality coverage above.
Related modalities